Vaccine Development

Oct 16, 2017
By BioPharm International Editors
Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.
Oct 16, 2017
By BioPharm International Editors
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
Oct 12, 2017
By BioPharm International Editors
The collaboration will focus on developing a novel and differentiated challenge model for respiratory syncytial virus.
Oct 12, 2017
By BioPharm International Editors
The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.
Oct 04, 2017
By BioPharm International Editors
Under Project BioShield, the agency could provide more than $170 million in funding to purchase and support late-stage development of Ebola vaccines and therapeutic drugs.
Oct 04, 2017
By BioPharm International Editors
The Danish biotechnology company has been awarded a sole-source BARDA contract valued at more than $539 million for a freeze-dried smallpox vaccine.
Oct 02, 2017
By BioPharm International Editors
A grant from the Bill & Melinda Gates Foundation will advance PnuVax’s pneumonia vaccine’s clinical development and biomanufacturing scale-up using a low-cost manufacturing approach.
Sep 20, 2017
By BioPharm International Editors
Under this partnership, Johnson & Johnson and BARDA will focus on the advanced development of a small-molecule drug and vaccine for the pandemic flu.
Sep 15, 2017
BioPharm International
Using a hollow microstructured transdermal system to deliver a vaccine directly to the dermis.
Sep 14, 2017
By BioPharm International Editors
Shingrix represents a new, possibly better alternative to existing treatments.
native1_300x100
lorem ipsum